Evaluate the Pharmacokinetics, Safety and Tolerability of JT001 Tablets

NCT05355077 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Development strategy adjustment

Conditions

Healthy Subjects

Interventions

DRUG: JT001 200mg Bid
DRUG: JT001 400mg Bid
DRUG: JT001 600mg Bid

Sponsor

Shanghai Vinnerna Biosciences Co., Ltd.